The U.S. is now averaging about 3.1 million COVID-19 vaccine doses administered per day. The increase coincides with a surge in the number of new cases across the country, including an outbreak in Michigan. (CNBC Weekly)

The Food and Drug Administration rejected Acadia Pharmaceuticals’ application to expand the use of Nuplazid, an anti-psychosis drug, to patients with dementia-related psychosis. In its rejection, the agency cited a “lack of statistical significance.” (STAT)

Johnson & Johnson is assessing the future of its flu therapy pipeline. The company is betting $780 million on a class of antiviral conjugate drugs out of Cidara Therapeutics that would target all flu strains, according to Cidara CEO Jeffrey Stein. (Endpoints News)

Health officials are urging AstraZeneca to cut ties with Emergent BioSolutions, a contractor that contaminated millions of doses at a Baltimore plant. J&J has assumed control of vaccine manufacturing at the plant. (Politico)

Researchers are studying a new potential COVID-19 vaccine, NVD-HXP-S, which uses a molecular design that boosts antibodies. The vaccine is currently entering clinical trials in Brazil, Mexico, Thailand and Vietnam. (The New York Times)